Similar Articles
Tofacitinib Versus Non-Tumor Necrosis Factor Biologics for Patients With Active Rheumatoid Arthritis
Yukio NAKAMURA, Takako SUZUKI, Hideshi YAMAZAKI, Hiroyuki KATO
DOI: 10.5606/ArchRheumatol.2018.6366
Issue: Volume 33 - Issue 2 - June 2018
3168
4311
Tofacitinib Induced Psoriasiform Lesion in a Patient With Rheumatoid Arthritis
Kemal Erol, Ragıp Ertaş
DOI: 10.46497/ArchRheumatol.2020.7541
Issue: Volume 35 - Issue 3 - September 2020
1584
2594
The Effects of Tofacitinib-Mediated Janus Kinase/Signal Transducers and Activators of the Transcription Signal Pathway Inhibition on Collagen Biosynthesis in Hepatic and Skin Fibroblast Cell Culture
Mehtap ŞAHİN, Hüseyin AYDIN, Ahmet ALTUN, Mehmet Emin DERİN, Ali ŞAHİN
DOI: 10.46497/ArchRheumatol.2020.7568
Issue: Volume 35 - Issue 3 - September 2020
2069
1791
Therapeutic Effects of Tofacitinib on Pristane-Induced Murine Lupus
Jiayi LIN, Yaqin ZHANG, Meihua WANG, Yang ZHANG, Pin LI, Yingping CAO, Xuwei YANG
DOI: 10.46497/ArchRheumatol.2022.8252
Issue: Volume 37 - Issue 2 - June 2022
1358
2141